What is eptifibatide?

Eptifibatide is an anti-decay injectide used in the treatment of acute chest or infarction pain and during coronary catheterization surgery that uses a catheter to try to achieve blood-lined chambers of the heart. Patients undergoing this treatment may benefit from the use of eptifibatide, which is sold under the Integlilin® brand to prevent the formation of blood clots during the procedure. Other use of eptifibatide include general blood thinning, which may be useful for patients with a history of hypertension or who undergo percutaneous coronary intervention. Eptifibatide works by stopping the binding of fibrinogen and other blood coagulation factors that can lead to a heart attack or stroke. Used in conjunction with aspirin or other medicines. It has been shown in the studies to prevent death and other episodes related to heart attack and congestive heart. Intravenous use and the nature of medicine and blood, which means that some preventive measures are required. For example, other medicines that may discourage blood clotting tend to interact well with eptifibatide. Before receiving eptifibatis, the patient should discuss all his medicines-including vitamins and other nutritional supplements, make sure that the doctor is aware whether these drugs include other inhibitors of platelets or anti-inflammatory drugs such as Aspirin.

Although unusual, some complications arise from the use of eptifibatis. At the entrance point for cardiac catheterization, the main bleeding and the properties of the blood that treats the drug can complicate efforts to stop flow. Low blood pressure can also be a complication of drug use, although it is said to be rare. Some complications result from human error or patient non -capital. Only patients are hospitalized, should be prescribed this medicine, partly due to the nature of the health condition that guarantees the use of the drug and partly because ofpossible side effects.

Eptifibatide was developed in 2001 scientists Cor Therapeutics Robert M. Scarborough and David Phillips. Cor Therapeutics was later acquired by Millennium Pharmaceuticals, which have sold and produced a medicine since 2011. In addition, Eptifibatide and its brand, Integlilin®, also work with Schering-Pough.

Eptifibatide is derived from the protein found in the poison of the southeast pygma of the rattle. The drug connects to a long list of drugs that reduce or prevent blood clotting. These include tirofiban and bivalirudin.